JPWO2020068261A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020068261A5 JPWO2020068261A5 JP2021516890A JP2021516890A JPWO2020068261A5 JP WO2020068261 A5 JPWO2020068261 A5 JP WO2020068261A5 JP 2021516890 A JP2021516890 A JP 2021516890A JP 2021516890 A JP2021516890 A JP 2021516890A JP WO2020068261 A5 JPWO2020068261 A5 JP WO2020068261A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- item
- immunomodulatory
- antibody
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002519 immonomodulatory effect Effects 0.000 claims description 242
- 102000037865 fusion proteins Human genes 0.000 claims description 230
- 108020001507 fusion proteins Proteins 0.000 claims description 230
- 102000008186 Collagen Human genes 0.000 claims description 106
- 108010035532 Collagen Proteins 0.000 claims description 106
- 229920001436 collagen Polymers 0.000 claims description 106
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 56
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 56
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 46
- 239000000427 antigen Substances 0.000 claims description 45
- 102000036639 antigens Human genes 0.000 claims description 45
- 108091007433 antigens Proteins 0.000 claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 230000002401 inhibitory effect Effects 0.000 claims description 33
- 108010076371 Lumican Proteins 0.000 claims description 31
- 102000005962 receptors Human genes 0.000 claims description 31
- 108020003175 receptors Proteins 0.000 claims description 31
- 239000003446 ligand Substances 0.000 claims description 30
- 102000012422 Collagen Type I Human genes 0.000 claims description 26
- 108010022452 Collagen Type I Proteins 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 22
- 230000004614 tumor growth Effects 0.000 claims description 22
- 102000004127 Cytokines Human genes 0.000 claims description 21
- 108090000695 Cytokines Proteins 0.000 claims description 21
- 210000002865 immune cell Anatomy 0.000 claims description 21
- 102000004266 Collagen Type IV Human genes 0.000 claims description 19
- 108010042086 Collagen Type IV Proteins 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 238000001727 in vivo Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 108091013859 Mimecan Proteins 0.000 claims description 14
- 102100026747 Osteomodulin Human genes 0.000 claims description 14
- 102000001732 Small Leucine-Rich Proteoglycans Human genes 0.000 claims description 14
- 108010040068 Small Leucine-Rich Proteoglycans Proteins 0.000 claims description 14
- 238000007792 addition Methods 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 238000012217 deletion Methods 0.000 claims description 14
- 230000037430 deletion Effects 0.000 claims description 14
- 108010078960 osteoadherin Proteins 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 230000003213 activating effect Effects 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 238000009792 diffusion process Methods 0.000 claims description 13
- 229940022399 cancer vaccine Drugs 0.000 claims description 12
- 238000009566 cancer vaccine Methods 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 11
- 102000019034 Chemokines Human genes 0.000 claims description 10
- 108010012236 Chemokines Proteins 0.000 claims description 10
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 102100026632 Mimecan Human genes 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 8
- 229940121354 immunomodulator Drugs 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 8
- 230000009885 systemic effect Effects 0.000 claims description 8
- 102000015827 Asporin Human genes 0.000 claims description 7
- 108050004044 Asporin Proteins 0.000 claims description 7
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 claims description 7
- 102000004954 Biglycan Human genes 0.000 claims description 7
- 108090001138 Biglycan Proteins 0.000 claims description 7
- 102100032925 Chondroadherin Human genes 0.000 claims description 7
- 102000004237 Decorin Human genes 0.000 claims description 7
- 108090000738 Decorin Proteins 0.000 claims description 7
- 101710139422 Eotaxin Proteins 0.000 claims description 7
- 102100023688 Eotaxin Human genes 0.000 claims description 7
- 102000017177 Fibromodulin Human genes 0.000 claims description 7
- 108010013996 Fibromodulin Proteins 0.000 claims description 7
- 102000003886 Glycoproteins Human genes 0.000 claims description 7
- 108090000288 Glycoproteins Proteins 0.000 claims description 7
- 101000611663 Homo sapiens Prolargin Proteins 0.000 claims description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 7
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 7
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 7
- 102100025913 Opticin Human genes 0.000 claims description 7
- 101710152613 Opticin Proteins 0.000 claims description 7
- 102100036036 Podocan Human genes 0.000 claims description 7
- 101710162126 Podocan Proteins 0.000 claims description 7
- 102100040659 Prolargin Human genes 0.000 claims description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 7
- 108010059427 chondroadherin Proteins 0.000 claims description 7
- 108010008217 nidogen Proteins 0.000 claims description 7
- 108010049224 perlecan Proteins 0.000 claims description 7
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 6
- 101710126486 Envelope glycoprotein D Proteins 0.000 claims description 6
- 101710126496 Envelope glycoprotein I Proteins 0.000 claims description 6
- 101001138059 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 2 Proteins 0.000 claims description 6
- 108090000172 Interleukin-15 Proteins 0.000 claims description 6
- 102100020858 Leukocyte-associated immunoglobulin-like receptor 2 Human genes 0.000 claims description 6
- 238000011467 adoptive cell therapy Methods 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 239000012642 immune effector Substances 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 101800002011 Amphipathic peptide Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 230000001270 agonistic effect Effects 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 102000051957 human ERBB2 Human genes 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 239000000863 peptide conjugate Substances 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 3
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 3
- 108700012434 CCL3 Proteins 0.000 claims description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 102000000013 Chemokine CCL3 Human genes 0.000 claims description 3
- 102000001326 Chemokine CCL4 Human genes 0.000 claims description 3
- 108010055165 Chemokine CCL4 Proteins 0.000 claims description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 3
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 3
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 3
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 3
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 3
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 3
- 102000039996 IL-1 family Human genes 0.000 claims description 3
- 108091069196 IL-1 family Proteins 0.000 claims description 3
- -1 INFα Proteins 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 102000000589 Interleukin-1 Human genes 0.000 claims description 3
- 108090000176 Interleukin-13 Proteins 0.000 claims description 3
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 claims description 3
- 101710107699 Interleukin-15 receptor subunit alpha Proteins 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 108010002586 Interleukin-7 Proteins 0.000 claims description 3
- 108010002335 Interleukin-9 Proteins 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 102000017578 LAG3 Human genes 0.000 claims description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 claims description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 3
- 108091008874 T cell receptors Proteins 0.000 claims description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 230000016396 cytokine production Effects 0.000 claims description 3
- 230000003013 cytotoxicity Effects 0.000 claims description 3
- 231100000135 cytotoxicity Toxicity 0.000 claims description 3
- 210000004443 dendritic cell Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 210000003630 histaminocyte Anatomy 0.000 claims description 3
- 230000016784 immunoglobulin production Effects 0.000 claims description 3
- 210000004964 innate lymphoid cell Anatomy 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102000016611 Proteoglycans Human genes 0.000 claims description 2
- 108010067787 Proteoglycans Proteins 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000004962 physiological condition Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 102100032114 Lumican Human genes 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 101710093458 ICOS ligand Proteins 0.000 claims 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 102000011681 Lumican Human genes 0.000 description 29
- 101100510626 Homo sapiens LAIR1 gene Proteins 0.000 description 20
- 101001065609 Homo sapiens Lumican Proteins 0.000 description 10
- 102000054090 human LUM Human genes 0.000 description 10
- 102000027307 Mimecan Human genes 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 102000004264 Osteopontin Human genes 0.000 description 5
- 108010081689 Osteopontin Proteins 0.000 description 5
- 108010008125 Tenascin Proteins 0.000 description 5
- 102000007000 Tenascin Human genes 0.000 description 5
- 108010031318 Vitronectin Proteins 0.000 description 5
- 102100035140 Vitronectin Human genes 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000004901 leucine-rich repeat Anatomy 0.000 description 3
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000042034 small leucine-rich proteoglycan (SLRP) family Human genes 0.000 description 1
- 108091079913 small leucine-rich proteoglycan (SLRP) family Proteins 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024074319A JP2024105392A (ja) | 2018-09-28 | 2024-05-01 | コラーゲンに局在化される免疫調節分子およびその方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738981P | 2018-09-28 | 2018-09-28 | |
| US62/738,981 | 2018-09-28 | ||
| PCT/US2019/043805 WO2020068261A1 (en) | 2018-09-28 | 2019-07-26 | Collagen-localized immunomodulatory molecules and methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024074319A Division JP2024105392A (ja) | 2018-09-28 | 2024-05-01 | コラーゲンに局在化される免疫調節分子およびその方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022502037A JP2022502037A (ja) | 2022-01-11 |
| JP2022502037A5 JP2022502037A5 (https=) | 2022-08-02 |
| JPWO2020068261A5 true JPWO2020068261A5 (https=) | 2022-08-02 |
| JP7557882B2 JP7557882B2 (ja) | 2024-09-30 |
Family
ID=67551439
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516890A Active JP7557882B2 (ja) | 2018-09-28 | 2019-07-26 | コラーゲンに局在化される免疫調節分子およびその方法 |
| JP2024074319A Pending JP2024105392A (ja) | 2018-09-28 | 2024-05-01 | コラーゲンに局在化される免疫調節分子およびその方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024074319A Pending JP2024105392A (ja) | 2018-09-28 | 2024-05-01 | コラーゲンに局在化される免疫調節分子およびその方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200102370A1 (https=) |
| EP (1) | EP3856763A1 (https=) |
| JP (2) | JP7557882B2 (https=) |
| KR (1) | KR20210068478A (https=) |
| CN (1) | CN112771071A (https=) |
| AU (1) | AU2019346335B2 (https=) |
| BR (1) | BR112021004383A2 (https=) |
| CA (1) | CA3113618A1 (https=) |
| IL (1) | IL281568A (https=) |
| MX (1) | MX2021003435A (https=) |
| SG (1) | SG11202100935TA (https=) |
| WO (1) | WO2020068261A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3856763A1 (en) | 2018-09-28 | 2021-08-04 | Massachusetts Institute of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| JP2022538974A (ja) | 2019-06-26 | 2022-09-07 | マサチューセッツ インスチテュート オブ テクノロジー | 免疫調節融合タンパク質－金属水酸化物錯体およびその方法 |
| GB202003618D0 (en) * | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| CH716227B1 (it) * | 2020-04-16 | 2020-11-30 | Contrad Swiss Sa | Composizione in gel per applicazione topica per la riduzione dell'infiammazione locale. |
| CN111849910B (zh) | 2020-05-27 | 2021-06-15 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| CN112358542A (zh) * | 2020-11-03 | 2021-02-12 | 安徽环球基因科技有限公司 | 一种重组cd36蛋白在哺乳动物细胞中的生产方法 |
| US12403179B2 (en) * | 2021-02-18 | 2025-09-02 | The Board Of Trustees Of The University Of Arkansas | Release of growth factors at wound healing stages |
| JP2024518680A (ja) * | 2021-03-19 | 2024-05-02 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節ポリペプチド及びその使用方法 |
| EP4314029A4 (en) * | 2021-03-31 | 2025-02-26 | The Regents of University of California | BISPECIFIC BINDER-LIGAND FUSIONS FOR TARGET PROTEIN DEGRADATION |
| JP2024516548A (ja) | 2021-04-08 | 2024-04-16 | ジョスリン ダイアビーティス センター インコーポレイテッド | 腎機能低下の診断及び予測の方法 |
| CA3217079A1 (en) * | 2021-05-05 | 2022-11-10 | Michael Schmidt | Fusion polypeptides |
| AU2022315305A1 (en) * | 2021-07-23 | 2024-02-01 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with cytokines |
| WO2023011575A1 (zh) * | 2021-08-04 | 2023-02-09 | 清华大学 | 一种靶向并杀伤病原体和/或肿瘤细胞的多功能融合蛋白药物 |
| CN113481167B (zh) * | 2021-08-04 | 2023-06-16 | 深圳市先康达生命科学有限公司 | 一种免疫细胞外泌体及其应用 |
| CA3233987A1 (en) * | 2021-10-06 | 2023-04-13 | Carl NOVINA | Engineered cytokine receptors for tunable adoptive cell therapy |
| WO2023081245A2 (en) * | 2021-11-03 | 2023-05-11 | University Of Kansas | Compositions including tumor-binding gmcsf fusion proteins and methods of using the same to treat solid tumors |
| US11873507B2 (en) * | 2021-11-29 | 2024-01-16 | Replicate Bioscience, Inc. | Compositions and methods for expression of IL-12 and IL-1RA |
| US20250101113A1 (en) * | 2022-01-11 | 2025-03-27 | Board Of Regents, The University Of Texas System | Anti-cd94 antibody and chimeric antigen receptor and methods of use thereof |
| WO2023212602A2 (en) * | 2022-04-27 | 2023-11-02 | Board Of Regents, The University Of Texas System | Cd30 hinge and/or transmembrane domain-based chimeric antigen receptors |
| CN114940712B (zh) * | 2022-06-01 | 2023-12-26 | 山西锦波生物医药股份有限公司 | 一种生物合成人体结构性材料的制备方法 |
| CN115806629A (zh) * | 2022-08-03 | 2023-03-17 | 深圳市先康达生命科学有限公司 | 一种自分泌IL-15与anti-CTLA4结合的融合蛋白及其应用 |
| WO2024168224A2 (en) * | 2023-02-10 | 2024-08-15 | Vernagen, LLC | Engineered nipah virus mrna vaccine |
| CN121693512A (zh) * | 2023-06-13 | 2026-03-17 | 芝加哥大学 | 包括用于治疗癌症的工程化il-7多肽和工程化il-12多肽的方法和组合物 |
| KR20260046383A (ko) * | 2023-07-25 | 2026-04-07 | 이뮤니티바이오, 인크. | Lair-2 및 tnt-트랩 조성물 및 방법 |
| CN117003895B (zh) * | 2023-08-09 | 2024-05-28 | 成都新诺明生物科技有限公司 | 一种含有IL2、Fc和PADRE的gE融合蛋白及其制备方法和应用 |
| WO2025080338A1 (en) * | 2023-10-11 | 2025-04-17 | Massachusetts Institute Of Technology | Cell-surface anchored cytokine therapy |
| CN117402235B (zh) * | 2023-10-25 | 2024-06-11 | 山西锦波生物医药股份有限公司 | 生物合成人体结构性材料iv型胶原蛋白的制备方法 |
| CN117903287B (zh) * | 2024-01-18 | 2025-01-28 | 西安巨子生物基因技术股份有限公司 | 一种具有抗氧化活性的重组iv型胶原蛋白及其应用 |
| WO2025194049A1 (en) * | 2024-03-15 | 2025-09-18 | Dana-Farber Cancer Institute, Inc. | Engineered immune cells and methods of using the same |
| WO2025245169A1 (en) * | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
| CN118978591A (zh) * | 2024-08-05 | 2024-11-19 | 河北康立德生物科技有限公司 | 抗隐球荚膜多糖单克隆抗体、其编码基因及其表达和应用 |
| CN118930649B (zh) * | 2024-09-26 | 2025-09-23 | 上海睿康生物科技有限公司 | Iv胶原蛋白的单克隆抗体制备及检测试剂盒应用 |
| CN119751647B (zh) * | 2024-12-31 | 2025-08-12 | 江苏创健医疗科技股份有限公司 | 重组iv型胶原蛋白及其制备方法与应用 |
| CN121086064B (zh) * | 2025-09-18 | 2026-04-03 | 深圳泰华赛尔生物科技有限公司 | 一种重组iii型人源化胶原蛋白及其制备方法与应用 |
Family Cites Families (198)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1151116A1 (en) * | 1999-02-19 | 2001-11-07 | Terumo Kabushiki Kaisha | Collagen-binding physiologically active polypeptide |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| US20020177571A1 (en) * | 2000-11-29 | 2002-11-28 | Gordon Erlinda M. | Targeted vectors for cancer immunotherapy |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| BR0206985A (pt) | 2001-01-29 | 2005-04-19 | Idec Pharma Corp | Anticorpos modificados e métodos de uso |
| NZ530212A (en) | 2001-06-13 | 2006-09-29 | Genmab As | An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR) |
| EP1849661A3 (en) | 2001-07-03 | 2007-11-14 | Delphi Korea Corporation | Side airbag for automobile and method of folding the same |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| ES2655912T3 (es) | 2002-11-08 | 2018-02-22 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| TW200423951A (en) | 2002-11-13 | 2004-11-16 | Ming-Chung Wong | Method of preparing anti-angiogenic drug from cartilage and chondrocytes and methods of use |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| ES2567634T3 (es) | 2004-02-09 | 2016-04-25 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina |
| JP2008539753A (ja) | 2005-05-09 | 2008-11-20 | グリクアート バイオテクノロジー アクチェンゲゼルシャフト | 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| ATE514712T1 (de) * | 2005-12-26 | 2011-07-15 | Yantai Zhenghai Bio Technology Co Ltd | Aktivierte collagen-gerüstmaterialien und ihre speziellen kondensierten aktiven restorationsfaktoren |
| US20090304686A1 (en) | 2006-03-08 | 2009-12-10 | Universotair Medisch Centrum Utrecht | Interfering in activation of an immune cell by influencing interaction of lair and collagen |
| DE102006031054B4 (de) | 2006-07-05 | 2010-08-05 | Hänel & Co. | Hochregal mit Lagergutanwahl |
| WO2008012629A2 (en) | 2006-07-24 | 2008-01-31 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
| US9334330B2 (en) | 2006-10-10 | 2016-05-10 | Universite De Nantes | Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers |
| WO2008060607A2 (en) | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
| US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
| US20110213288A1 (en) | 2007-04-23 | 2011-09-01 | The Board Of Regents, The University Of Texas System | Device And Method For Transfecting Cells For Therapeutic Uses |
| WO2008131445A1 (en) | 2007-04-23 | 2008-10-30 | The Board Of Regents, The University Of Texas System | Device and method for transfecting cells for therapeutic use |
| US7468685B1 (en) | 2007-08-20 | 2008-12-23 | Fairchild Semiconductor Corporation | Clockless serialization using delay circuits |
| KR20100132535A (ko) | 2008-03-31 | 2010-12-17 | 글락소 그룹 리미티드 | 약물 융합체 및 컨주게이트 |
| CN101335956B (zh) | 2008-08-05 | 2011-10-05 | 国民技术股份有限公司 | 借助误码率统计数据判断通信距离的系统和方法 |
| EP2169837B1 (en) | 2008-09-29 | 2013-01-30 | Telefonaktiebolaget LM Ericsson (publ) | Technique for suppressing noise in a transmitter device |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| US8457578B2 (en) | 2008-12-30 | 2013-06-04 | Qualcomm Incorporated | Discrete time receiver |
| WO2010093771A1 (en) | 2009-02-11 | 2010-08-19 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with temozolomide |
| US20100322909A1 (en) | 2009-06-17 | 2010-12-23 | The University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Th1-associated micrornas and their use for tumor immunotherapy |
| CN101998390B (zh) | 2009-08-27 | 2015-03-25 | 华为技术有限公司 | 保证通信安全的方法及设备 |
| AU2010312594B2 (en) | 2009-10-27 | 2013-06-20 | Delta-Fly Pharma, Inc. | Novel 5-fluorouracil derivative |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US20110104128A1 (en) | 2009-10-30 | 2011-05-05 | The Board Of Regents, The University Of Texas System | Device and Method for Transfecting Cells for Therapeutic Use |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| EA022983B1 (ru) | 2010-04-13 | 2016-04-29 | Бристол-Майерс Сквибб Компани | Белки на основе структурного домена фибронектина, связывающие pcsk9 |
| WO2011150420A1 (en) | 2010-05-28 | 2011-12-01 | Baylor College Of Medicine | Modified gold nanoparticles for therapy |
| DK3323830T3 (da) | 2010-06-19 | 2023-09-25 | Memorial Sloan Kettering Cancer Center | Anti-gd2 antibodies |
| CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| US9163258B2 (en) | 2010-07-23 | 2015-10-20 | Fred Hutchinson Cancer Research Center | Method for the treatment of obesity |
| CA2805097A1 (en) | 2010-07-28 | 2012-02-02 | DePuy Synthes Products, Inc. | System or bone fixation using biodegradable screw having radial cutouts |
| US9487800B2 (en) | 2010-09-08 | 2016-11-08 | Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| CN108424462A (zh) | 2010-10-27 | 2018-08-21 | 贝勒医学院 | 使t细胞重定向针对cd70阳性恶性肿瘤的嵌合cd27受体 |
| WO2012071420A1 (en) | 2010-11-23 | 2012-05-31 | The Trustees Of Columbia University In The City Of New York | Enzyme combinations to reduce brain tissue swelling |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| ES2791716T3 (es) | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
| CN102115495B (zh) * | 2010-12-24 | 2012-07-04 | 中国人民解放军第四军医大学 | 胶原靶向治疗增生性瘢痕蛋白药物的制备及应用 |
| KR101796322B1 (ko) | 2011-01-07 | 2017-12-01 | 삼성전자주식회사 | 항법 알고리즘을 이용한 위치 정보 검출 장치 및 방법 |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| SG193023A1 (en) | 2011-02-11 | 2013-10-30 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| WO2012148552A2 (en) | 2011-02-24 | 2012-11-01 | The Research Foundation Of State University Of New York | Rectifying electromagnetic nanosensors |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| GB201108236D0 (en) | 2011-05-17 | 2011-06-29 | Ucl Business Plc | Method |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| EP3549611B1 (en) | 2011-07-29 | 2021-06-30 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| WO2013051718A1 (ja) | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| JP6074435B2 (ja) | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| US8772058B2 (en) | 2012-02-02 | 2014-07-08 | Harris Corporation | Method for making a redistributed wafer using transferrable redistribution layers |
| WO2013121960A1 (ja) | 2012-02-13 | 2013-08-22 | 電気化学工業株式会社 | クロロプレンゴム組成物、該クロロプレンゴム組成物を用いた接着剤組成物 |
| WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| CA3205751A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| MX2014010185A (es) | 2012-02-22 | 2014-11-14 | Univ Pennsylvania | Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion. |
| JP6375289B2 (ja) | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| EA033110B1 (ru) | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| US9777055B2 (en) | 2012-04-20 | 2017-10-03 | Thomas Jefferson University | Engineered antibody for inhibition of fibrosis |
| ES2719495T5 (en) | 2012-05-07 | 2025-09-10 | Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| US9879062B2 (en) | 2012-07-03 | 2018-01-30 | Ecole Polytechnique Federale De Lausanne | Protein-binding peptide isolated from placenta growth factor |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| AU2013289979A1 (en) | 2012-07-13 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Methods of assessing the suitability of transduced T cells for administration |
| JP5822798B2 (ja) | 2012-08-08 | 2015-11-24 | 三菱電機株式会社 | 断熱箱体及びこの断熱箱体を備えた冷蔵庫 |
| US20140065629A1 (en) | 2012-08-29 | 2014-03-06 | Israel Barken | Methods of treating diseases |
| EP2893003B1 (en) | 2012-09-04 | 2021-03-31 | Inven2 AS | Selective and controlled expansion of educated nk cells |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| EP2893566B1 (fr) | 2012-09-05 | 2016-05-18 | Institut National des Sciences Appliquées de Lyon | Procede de fabrication d'un transistor a effet de champ a jonction jfet |
| WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| EP2906684B8 (en) | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US20140120136A1 (en) | 2012-10-12 | 2014-05-01 | The Babraham Institute | Mir-155 enhancement of cd8+ t cell immunity |
| JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| TW201446794A (zh) | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向 |
| DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| US20140274801A1 (en) | 2013-03-14 | 2014-09-18 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified t cells |
| US9587237B2 (en) | 2013-03-14 | 2017-03-07 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| US9393268B2 (en) | 2013-03-15 | 2016-07-19 | Thomas Jefferson University | Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same |
| US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| JP2016515587A (ja) | 2013-03-29 | 2016-05-30 | メリマック ファーマシューティカルズ インコーポレーティッド | 軟骨結合性融合タンパク質 |
| ES3011466T3 (en) | 2013-04-18 | 2025-04-07 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| WO2014201378A1 (en) | 2013-06-13 | 2014-12-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy |
| WO2014201319A1 (en) | 2013-06-14 | 2014-12-18 | The University Of Houston System | Targeting tumor neovasculature with modified chimeric antigen receptors |
| DE102013212604A1 (de) | 2013-06-28 | 2014-12-31 | Robert Bosch Gmbh | Bearbeitungswerkzeug |
| EP3021853A1 (en) | 2013-07-18 | 2016-05-25 | Baylor College Of Medicine | Method of enhancing potency of immune cells |
| FR3009192B1 (fr) | 2013-07-31 | 2015-09-04 | Oreal | Composition cosmetique anhydre comprenant de l'alkylcellulose, au moins un ester ramifie de dextrine et au moins un alcool gras |
| NO335489B1 (no) | 2013-08-27 | 2014-12-22 | Langåker John Magne | Multifunksjons varmepumpe |
| US9351129B2 (en) | 2013-08-30 | 2016-05-24 | Hubbell Incorporated | WiFi hazardous area VoIP paging telephone and system |
| WO2015038684A1 (en) | 2013-09-10 | 2015-03-19 | Polyera Corporation | Attachable article with signaling, split display and messaging features |
| KR102339240B1 (ko) | 2013-10-15 | 2021-12-15 | 더 스크립스 리서치 인스티튜트 | 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도 |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| EP3103153B1 (en) | 2014-02-05 | 2017-08-30 | Elcogen OY | Assembly method and arrangement for a cell system |
| KR102229770B1 (ko) | 2014-03-17 | 2021-03-18 | 나믹스 가부시끼가이샤 | 수지 조성물 |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| CA2945335A1 (en) | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| WO2016054107A1 (en) | 2014-09-29 | 2016-04-07 | Counterpoint Biomedica Llc | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers |
| JP2017531430A (ja) | 2014-10-07 | 2017-10-26 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃａｒによって誘導される免疫細胞の活性を調節するための方法 |
| BR112017008042A2 (pt) | 2014-10-20 | 2017-12-26 | Juno Therapeutics Inc | métodos e composições para dosagem em terapia de célula adotiva |
| WO2016069282A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| KR102376244B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| CA3197849A1 (en) | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| JP6865688B2 (ja) | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| MA41433A (fr) | 2015-01-26 | 2017-12-05 | Baylor College Medicine | Cellules immunitaires universelles pour l'immunothérapie anticancéreuse |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| WO2016149254A1 (en) | 2015-03-17 | 2016-09-22 | Chimera Bioengineering, Inc. | Smart car devices, de car polypeptides, side cars and uses thereof |
| KR20260048600A (ko) | 2015-03-27 | 2026-04-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 변형된 t 세포 및 이의 제조 및 사용 방법 |
| SG11201708516YA (en) | 2015-04-17 | 2017-11-29 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| CN104894068A (zh) | 2015-05-04 | 2015-09-09 | 南京凯地生物科技有限公司 | 一种利用CRISPR/Cas9制备CAR-T细胞的方法 |
| IL295224B2 (en) | 2015-05-28 | 2025-07-01 | Kite Pharma Inc | Methods of conditioning patients for t cell therapy |
| EP3313871A1 (en) | 2015-06-26 | 2018-05-02 | Institute for Research in Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
| AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| EP3341410B1 (en) | 2015-08-24 | 2021-06-02 | Cellectis | Chimeric antigen receptors with integrated controllable functions |
| US20180258149A1 (en) | 2015-09-17 | 2018-09-13 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| JP2019508036A (ja) | 2016-02-16 | 2019-03-28 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫療法組成物及び方法 |
| CN106480097A (zh) | 2016-10-13 | 2017-03-08 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用 |
| CN106399375A (zh) | 2016-08-31 | 2017-02-15 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法 |
| CN106591363A (zh) | 2016-11-11 | 2017-04-26 | 广东万海细胞生物科技有限公司 | 一种通用型异体car‑t细胞制备方法及应用 |
| CN106755088A (zh) | 2016-11-11 | 2017-05-31 | 广东万海细胞生物科技有限公司 | 一种自体car‑t细胞制备方法及应用 |
| KR102056066B1 (ko) | 2016-12-09 | 2019-12-17 | 진메디신 주식회사 | 세포외 기질 분해 인자를 발현하는 재조합 아데노바이러스를 포함하는 항암용 조성물 |
| CA3047312A1 (en) * | 2016-12-15 | 2018-06-21 | The Brigham And Women's Hospital, Inc. | Tissue-based biologics for the treatment of inflammatory and autoimmune disorders |
| US10913779B2 (en) * | 2017-01-25 | 2021-02-09 | Counterpoint Biomedica Llc | Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections |
| TWI844524B (zh) * | 2018-02-09 | 2024-06-11 | 義大利商費洛根公司 | 靶向edb之il-12組合物 |
| AU2019232729B2 (en) * | 2018-03-05 | 2024-08-08 | The University Of Chicago | Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines |
| CN112638403A (zh) * | 2018-07-03 | 2021-04-09 | 康泰伦特药物解决方案有限责任公司 | 包括饰胶蛋白聚糖的多功能蛋白质分子及其用途 |
| EP3856763A1 (en) | 2018-09-28 | 2021-08-04 | Massachusetts Institute of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| IL303712A (en) * | 2020-12-18 | 2023-08-01 | Cullinan Amber Corp | Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereofלטו |
-
2019
- 2019-07-26 EP EP19750220.6A patent/EP3856763A1/en active Pending
- 2019-07-26 KR KR1020217012024A patent/KR20210068478A/ko not_active Ceased
- 2019-07-26 WO PCT/US2019/043805 patent/WO2020068261A1/en not_active Ceased
- 2019-07-26 JP JP2021516890A patent/JP7557882B2/ja active Active
- 2019-07-26 CA CA3113618A patent/CA3113618A1/en active Pending
- 2019-07-26 BR BR112021004383-7A patent/BR112021004383A2/pt unknown
- 2019-07-26 SG SG11202100935TA patent/SG11202100935TA/en unknown
- 2019-07-26 US US16/523,965 patent/US20200102370A1/en not_active Abandoned
- 2019-07-26 AU AU2019346335A patent/AU2019346335B2/en active Active
- 2019-07-26 MX MX2021003435A patent/MX2021003435A/es unknown
- 2019-07-26 CN CN201980063880.8A patent/CN112771071A/zh active Pending
-
2021
- 2021-03-16 IL IL281568A patent/IL281568A/en unknown
-
2022
- 2022-11-18 US US18/056,825 patent/US12227559B2/en active Active
-
2024
- 2024-05-01 JP JP2024074319A patent/JP2024105392A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020068261A5 (https=) | ||
| JP2022502037A5 (https=) | ||
| JP7720950B2 (ja) | Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 | |
| US11965007B2 (en) | IL-15-based fusions to IL-7 and IL-21 | |
| CN113286811B (zh) | 改善过继性细胞疗法的效力和安全性 | |
| CN106659775B (zh) | 基于il-15的分子及其方法和用途 | |
| CN109496217B (zh) | 具有cd3结合域的基于多聚体il-15的分子的构造和表征 | |
| JP7713390B2 (ja) | がん治療のための免疫療法 | |
| US12551530B2 (en) | Immune cell function | |
| US20240150482A1 (en) | Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof | |
| KR20230155521A (ko) | 면역 세포 기능의 향상 | |
| CN116997564A (zh) | 改善免疫细胞功能 | |
| WO2020205516A1 (en) | Dosing of a bispecific antibody that binds pd1 and ctla4 | |
| JP2022524994A (ja) | Ｔ細胞受容体及びその使用方法 | |
| JP2024508509A (ja) | 抗ｃｄ３０モノクローナル抗体及びキメラ抗原受容体 |